# A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

> **NCT05347485** · PHASE2 · COMPLETED · sponsor: **Janssen Scientific Affairs, LLC** · enrollment: 86 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cilta-cel
- **DRUG:** Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)

## Key facts

- **NCT ID:** NCT05347485
- **Lead sponsor:** Janssen Scientific Affairs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-13
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-12-15
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05347485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05347485, "A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05347485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*